文献速递骨软组织肉瘤与黑色素瘤

实测与基因预测的血浆YKL-40水平与黑色素瘤死亡率

Measured and genetically predicted plasma YKL-40 levels and melanoma mortality.
PubMed 文献 · Eur J Cancer · 2019-01-01

研究纳入两个队列共4031例黑色素瘤患者,随访死亡率终点长达20年,并对CHI3L1 rs4950928进行基因分型、在2165例中测定血浆YKL-40。结果显示实测血浆YKL-40升高与死亡率增加相关,而基因预测的YKL-40水平与死亡率无显著关联,提示YKL-40更可能是标志物而非死亡原因。

要点

  • 实测血浆YKL-40第96-100百分位较第1-95百分位死亡风险增加,校正年龄性别HR为1.52。
  • 实测血浆YKL-40每增加10百分位,死亡风险校正HR为1.07,在局限性黑色素瘤中更明显。
  • 基因预测的YKL-40水平与死亡率无显著关联,提示YKL-40可能不是死亡原因。

核心结论

  • 实测血浆YKL-40升高与黑色素瘤患者死亡率增加相关,而基因预测的YKL-40水平与死亡率无显著关联。
  • 血浆YKL-40更可能是死亡率增加的标志物,而非其原因。

研究设计与样本

  • 研究纳入两个队列:医院门诊来源的2618例黑色素瘤患者和一般人群来源的1413例黑色素瘤患者,合计4031例,随访死亡率终点最长20年。
  • 所有患者均对CHI3L1 rs4950928进行基因分型,该位点可高度预测终生血浆YKL-40水平;其中2165例患者测定了血浆YKL-40水平。

主要发现

  • 医院黑色素瘤队列中,实测血浆YKL-40处于第96-100百分位 versus 第1-95百分位的年龄和性别校正死亡风险比HR为1.52(95%CI 1.07-2.16)。
  • 医院黑色素瘤队列中,实测血浆YKL-40每增加10百分位的年龄和性别校正死亡风险比HR为1.07(95%CI 1.02-1.11),在局限性黑色素瘤患者中最为明显。
  • CHI3L1 rs4950928每个C等位基因与血浆YKL-40水平升高相关:医院黑色素瘤队列升高32%(p=6×10^-48),一般人群黑色素瘤队列升高43%(p=7×10^-13)。
  • 合并队列中多因素校正后,实测血浆YKL-40升高的风险比为1.04(95%CI 1.00-1.09),基因预测血浆YKL-40升高的风险比为0.98(95%CI 0.86-1.12)。

临床怎么用

  • 血浆YKL-40可作为黑色素瘤患者死亡风险的监测标志物,尤其对局限性黑色素瘤患者可能具有提示价值。
  • 基因预测的YKL-40水平与死亡率无显著关联,提示检测CHI3L1 rs4950928基因型不能替代血浆YKL-40测定用于风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: High plasma levels of YKL-40 might be associated with mortality in patients with melanoma, and it is unknown if YKL-40 is causally related to mortality. EXPERIMENTAL DESIGN: We studied two cohorts: 2618 patients with melanoma from hospital clinics and 1413 general population patients with melanoma, totalling 4031 patients followed up for mortality end-points for up to 20 years. All were genotyped for CHI3L1 rs4950928, highly predictive of lifelong plasma YKL-40, and plasma YKL-40 levels were measured in 2165 patients. We tested the hypotheses that measured and genetically predicted high plasma YKL-40 are associated with increased mortality in patients with melanoma. RESULTS: For the hospital melanoma cohort, age- and sex-adjusted hazard ratios for death in individuals with measured plasma YKL-40 in the 96-100th percentile versus 1-95th percentile and per 10-percentile increase were 1.52 (95% confidence interval, 1.07-2.16) and 1.07 (1.02-1.11), respectively, most pronounced for patients with localised melanomas. Each C-allele of the CHI3L1 rs4950928 genotype was associated with plasma YKL-40 level increases of 32% in the hospital melanoma cohort (p = 6 × 10-48) and 43% in the general population melanoma cohort (p = 7 × 10-13). Multifactorially adjusted ratios for these increases in the combined cohorts were 1.04 (1.00-1.09) observationally for measured plasma YKL-40 and 0.98 (0.86-1.12) for the genetically predicted plasma YKL-40. CONCLUSION: Measured, but not genetically predicted, increasing plasma YKL-40 was associated with increased mortality in patients with melanoma. Plasma YKL-40 is a marker but less likely to be a cause of increased mortality in patients with melanoma.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ismail H, Helby J, Hölmich LR, et al. Measured and genetically predicted plasma YKL-40 levels and melanoma mortality. Eur J Cancer. 2019. PMID: 31563729. doi:10.1016/j.ejca.2019.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。